Bicycle Therapeutics and ThromboGenics form an alliance to develop bicycle peptide inhibitors for the treatment of ophthalmic diseases

Cambridge, UK. Bicycle Therapeutics, a next generation biotherapeutics company developing novel bicyclic peptides, today announced that it has entered into a collaboration and license agreement with ThromboGenics NV to develop potent and selective bicyclic peptide inhibitors against a specific drug target of interest for the treatment of ophthalmic diseases, such as diabetic macular edema (DME). Read More